Xizang Haisco Pharmaceutical Group Co.

Xizang Haisco Pharmaceutical Group Co.

Xizang Haisco Pharmaceutical Group was founded in 2000 by wang junmin, a tibetan entrepreneur who built the company from a local tibetan pharmaceutical operation into a modern publicly traded enterprise listed on the shenzhen stock exchange in 2017. the firm's wealth originates from wang junmin's controlling stake in the listed entity, which has a market cap of roughly 25 billion yuan. The family office invests across pharmaceutical research and development, traditional chinese medicine, and biotech. it has made direct investments in clinical-stage drug development programs, focusing on oncology and metabolic diseases. known portfolio companies include its own listed entity, Haisco Pharmaceutical Group, which has over 200 approved drug products and a pipeline of 50+ new drug candidates. the firm operates primarily within china, but has exploration of international markets through licensing deals and clinical trials in North America and Asia. The firm's team includes a small group of investment professionals based in shannan and likely chengdu. the office is leanly structured, with the family maintaining direct control over investment decisions. no additional offices or philanthropic vehicles are publicly documented. the firm went public in 2017, but the family office entity is not separately registered or disclosed. The structural differentiator of Xizang Haisco is its dual identity as both a publicly traded pharmaceutical company and a single-family office. the wang family retains majority ownership of the public entity while using the office to manage personal wealth and direct biotech investments. this hybrid structure is uncommon among chinese family offices, which typically separate operating businesses from investment vehicles.